NVS — Novartis AG stock price and chart

NVS

Novartis AGStock · Health CareMSCI EAFE 1.3% · MSCI World 0.3% · MSCI ACWI 0.3%

$140.37-0.39%

as of market close, Sep 18, 2026

☾ AH $140.03 -0.24%

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDD

20162019202120242026

70.080.090.0100.0110.0120.0130.0140.0150.0160.0020.0M$140.37

2026-09-18

Price$140.37

MA20$151.54

MA50$142.41

Vol8.2M

What would $1,000 invested in NVS be worth today? →

NVS returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $140.37
Change YTD: +1.81%
Next earnings: Oct 27, 2026 · Before open
Market cap: 267.8B2017-03 158B2026-09 267.8B+69.5% over the window
Enterprise value: 257.2B
Shares outstanding: 1.9B2016-12 2.4B2025-12 1.9B-19.6% over the window
52W low: $121.57
52W high: $170.46
From 52W high: -17.65%
From 52W low: +15.46%
52W range: 38%
Beta: 0.46

Volume

Rel volume: 1.04×
30D volume: 2.2M
30D $ vol: 321.5M

Fundamentals

EPS (ttm): $7.152016-12 $2.802025-12 $7.15+155.4% over the window
FCF (ttm): 19.1B
FCF/share: $10.03
Book value/share: $24.182016-12 $31.552025-12 $24.18-23.4% over the window
ROE: 30.28%2016-12 8.9%2025-12 30.3%+238.5% over the window
ROA: 12.59%2017-12 5.8%2025-12 12.6%+117.5% over the window
Current ratio: 1.122017-12 1.212025-12 1.12-7.4% over the window

Growth (CAGR, ttm) · 10Y

Net income: +17.00%2024-12-31 → 2025-12-3111.9B → 14B (+17.0% total)+26.16%2022-12-31 → 2025-12-317B → 14B (+100.8% total)+11.59%2020-12-31 → 2025-12-318.1B → 14B (+73.1% total)n/a
Shares: -3.39%2024-12-31 → 2025-12-312B → 1.9B (-3.4% total)-3.44%2022-12-31 → 2025-12-312.1B → 1.9B (-10.0% total)-3.30%2020-12-31 → 2025-12-312.3B → 1.9B (-15.4% total)n/a

Per-share growth (CAGR, ttm) · 10Y

EPS: +21.82%2024-12-31 → 2025-12-31$5.87 → $7.15 (+21.8% total)+31.14%2022-12-31 → 2025-12-31$3.17 → $7.15 (+125.6% total)+15.23%2020-12-31 → 2025-12-31$3.52 → $7.15 (+103.1% total)n/a
Book value/share: +8.41%2024-12-31 → 2025-12-31$22.30 → $24.18 (+8.4% total)-4.77%2022-12-31 → 2025-12-31$28.00 → $24.18 (-13.6% total)-0.73%2020-12-31 → 2025-12-31$25.08 → $24.18 (-3.6% total)n/a
Dividend/share: +6.15%2024-12-31 → 2025-12-31$3.86 → $4.10 (+6.1% total)+4.98%2022-12-31 → 2025-12-31$3.54 → $4.10 (+15.7% total)+5.76%2020-12-31 → 2025-12-31$3.10 → $4.10 (+32.3% total)n/a
Price: +14.80%2025-09-18 → 2026-09-18$122.29 → $140.37 (+14.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+11.20%2023-09-18 → 2026-09-18$102.07 → $140.37 (+37.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+10.95%2021-09-17 → 2026-09-18$83.48 → $140.37 (+68.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+7.04%2016-09-16 → 2026-09-18$71.09 → $140.37 (+97.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +18.29%2025-09-18 → 2026-09-18$118.68 → $140.37 (+18.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.08%2023-09-18 → 2026-09-18$92.09 → $140.37 (+52.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.15%2021-09-17 → 2026-09-18$69.31 → $140.37 (+102.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+10.98%2016-09-16 → 2026-09-18$49.51 → $140.37 (+183.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 19.6×2017-03 23.592026-09 19.18-18.7% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 15.2×2017-03 19.112026-09 15.18-20.6% over the window
Fwd P/E: 14.3×
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 5.8×2017-03 2.112026-09 5.81+175.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 14.0×
EV/EBITDA (fy): 14.6×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 7.15%
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 2.92%
Dividend/share (fwd): $4.10
Buyback yield (realized, 1y)1 − shares_at(2025-12-31) ÷ shares_at(2024-12-31) = 1 − 1.91B ÷ 1.98B. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 3.39%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (3.39%) + dividends paid over that year ($7.8B) ÷ market_cap_at(2024-12-31) ($192.2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 7.46%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($9.1B) ÷ today's market cap ($267.8B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 3.41%2016-12 0.6%2025-12 3.5%+452.3% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $9.1B + TTM dividends $7.8B) ÷ today's market cap ($267.8B). Same caveat as the cash buyback yield.: 6.32%2016-12 4.7%2025-12 6.4%+36.2% over the window

Vs own 10Y history

P/E: 46th
P/OI: 4th
P/B: 91st

Bar = where today’s multiple sits in NVS’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-09-18

-0.39%

+2.34%

-9.18%

-4.56%

YTD

+1.81%

+14.78%

+68.15%

Financial statements

Open full NVS financials →

Loading financial statements…

Ticker	Name	1M	1D
NVO	Novo Nordisk A/S	-5.40%	+0.12%
SNY	Sanofi ADS	-5.54%	-1.53%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-1.82%	-1.65%
ARGX	argenx SE American Depositary Shares	-0.27%	-0.55%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	+4.76%	-0.73%
NTRA	Natera Inc.	+18.51%	+0.84%
TEVA	Teva Pharmaceutical Industries Limited American Depositary Shares	+6.56%	-0.54%
RVMD	Revolution Medicines Inc.	-11.60%	-3.04%

Novartis AG (NVS) trades at $140.37 with a live price and an interactive chart covering 29+ years of daily price history, plus key valuation metrics. ChartRow also publishes NVS’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full NVS financial statements →

NVS — Novartis AG price, chart and key statistics